JPH0122267B2 - - Google Patents

Info

Publication number
JPH0122267B2
JPH0122267B2 JP51031184A JP3118476A JPH0122267B2 JP H0122267 B2 JPH0122267 B2 JP H0122267B2 JP 51031184 A JP51031184 A JP 51031184A JP 3118476 A JP3118476 A JP 3118476A JP H0122267 B2 JPH0122267 B2 JP H0122267B2
Authority
JP
Japan
Prior art keywords
group
halogen atom
alkyl
methyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51031184A
Other languages
English (en)
Japanese (ja)
Other versions
JPS51118773A (en
Inventor
Robaato Buritein Deuitsudo
Dagurasu Buraun Edowaado
Hetsupuwaasu Warutaa
Yosefu Suteishii Girubaato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB11644/75A external-priority patent/GB1502312A/en
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of JPS51118773A publication Critical patent/JPS51118773A/ja
Publication of JPH0122267B2 publication Critical patent/JPH0122267B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP51031184A 1975-03-20 1976-03-22 Quinolone alkane acid derivatives preparation method and pharmaceutical composite containing derivatives Granted JPS51118773A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB11644/75A GB1502312A (en) 1975-03-20 1975-03-20 Quinolone derivatives
GB4204375 1975-10-14

Publications (2)

Publication Number Publication Date
JPS51118773A JPS51118773A (en) 1976-10-18
JPH0122267B2 true JPH0122267B2 (OSRAM) 1989-04-25

Family

ID=26248416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51031184A Granted JPS51118773A (en) 1975-03-20 1976-03-22 Quinolone alkane acid derivatives preparation method and pharmaceutical composite containing derivatives

Country Status (19)

Country Link
US (1) US4066651A (OSRAM)
JP (1) JPS51118773A (OSRAM)
AU (1) AU1147676A (OSRAM)
CS (1) CS188273B2 (OSRAM)
DD (1) DD124117A5 (OSRAM)
DE (1) DE2611824A1 (OSRAM)
DK (1) DK115376A (OSRAM)
ES (1) ES446234A1 (OSRAM)
FI (1) FI760729A7 (OSRAM)
FR (1) FR2304342A1 (OSRAM)
HU (1) HU172032B (OSRAM)
IE (1) IE43079B1 (OSRAM)
IL (1) IL49126A0 (OSRAM)
LU (1) LU74594A1 (OSRAM)
NL (1) NL7602834A (OSRAM)
NO (1) NO760993L (OSRAM)
PT (1) PT64921B (OSRAM)
SE (1) SE434394B (OSRAM)
SU (1) SU648090A3 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK0382185T3 (da) * 1989-02-10 1994-07-04 Otsuka Pharma Co Ltd Carbostyrilderivater
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1992004327A1 (en) * 1990-09-07 1992-03-19 Schering Corporation Antiviral compounds and antihypertensive compounds
CA2066104C (en) * 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
EP0543018B1 (en) * 1991-06-07 1996-01-10 Otsuka Pharmaceutical Co., Ltd. Antidiabetic agent
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
KR20020038741A (ko) 1999-08-27 2002-05-23 윌리암 엘. 레스페스 안드로겐 수용체 조절 화합물 및 방법
JP2003529545A (ja) 1999-09-14 2003-10-07 リガンド・ファーマシューティカルズ・インコーポレイテッド 改善された薬理学的プロファイルを有するrxrモジュレーター
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
CA2536349A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AU2008297877C1 (en) * 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
DE602008004794D1 (de) * 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온
US8785486B2 (en) * 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2220216A4 (en) * 2007-11-15 2013-03-20 Univ Laval PROCESS FOR REGULATING THE PROSTAGLANDIN F-SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772301A (en) * 1971-11-22 1973-11-13 Warner Lambert Co (4-substituted)4-(methylsulfinyl)methylcarbostyrils

Also Published As

Publication number Publication date
HU172032B (hu) 1978-05-28
NL7602834A (nl) 1976-09-22
IL49126A0 (en) 1976-05-31
DE2611824A1 (de) 1976-09-30
DE2611824C2 (OSRAM) 1987-06-19
ES446234A1 (es) 1977-10-01
DD124117A5 (OSRAM) 1977-02-02
SU648090A3 (ru) 1979-02-15
NO760993L (OSRAM) 1976-09-21
FI760729A7 (OSRAM) 1976-09-21
JPS51118773A (en) 1976-10-18
FR2304342A1 (fr) 1976-10-15
FR2304342B1 (OSRAM) 1979-09-21
PT64921A (en) 1976-04-01
IE43079L (en) 1976-09-20
SE434394B (sv) 1984-07-23
PT64921B (en) 1977-08-24
AU1147676A (en) 1977-09-01
IE43079B1 (en) 1980-12-17
SE7602339L (sv) 1976-09-21
DK115376A (da) 1976-09-21
CS188273B2 (en) 1979-02-28
US4066651A (en) 1978-01-03
LU74594A1 (OSRAM) 1977-05-06

Similar Documents

Publication Publication Date Title
JPH0122267B2 (OSRAM)
JPH0262532B2 (OSRAM)
US4457927A (en) Pyrido[2,1-b]quinazolinone derivatives and the preparation and use thereof
CS208153B2 (en) Method of making the 5-/4-pyridyl/-6-/4-fluorphebyl/-2,3-dihydroimidazo 2,1-b thiazole
KR100378892B1 (ko) 류코트리엔-길항활성을갖는벤조피란유도체
JPWO1994024087A1 (ja) リグナン系化合物の製造方法
JPH0146514B2 (OSRAM)
JPH02346B2 (OSRAM)
DD145101A5 (de) Verfahren zur herstellung von inda yl-derivaten
JPS6236382A (ja) チエノピリドン治療薬及びその製法
US4755509A (en) Heterocyclic aldose reductase inhibitors and methods of using them
JPH0390063A (ja) 二置換された(キノリン―2―イル―メトキシ)フエニル酢酸誘導体
JPS6228793B2 (OSRAM)
US4128666A (en) 4 AND 5-Halo substituted 2-indanamine compounds
US4138490A (en) Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives
CA2433623A1 (en) Pyridine derivatives useful as cyclooxygenase inhibitor
JPH01228963A (ja) 5‐アミノ‐4,6‐ジハロゲノ‐ピリジン類の製法
JPH04244063A (ja) フエニルスルホンアミド置換されたピリジンアルケン−および−アミノオキシアルカンカルボン酸誘導体
US3886161A (en) 2-Piperazino-3-cyano-5-phenyl-pyridines
JPH06157543A (ja) 新規のチエノチアジン誘導体、その製造方法並びにその使用方法
JPS6333378A (ja) ピリド〔1,8〕ナフチリジノン、その製造方法及びそれらの化合物を含有する製剤
Elderfield et al. Synthesis of 2-Phenyl-4-chloroquinolines1
JPS64951B2 (OSRAM)
JPS6216469A (ja) 2−置換シクロヘプトイミダゾ−ル誘導体、抗潰瘍剤及びその製造方法
US3686180A (en) Substituted 9-lower alkylacridine-4-carboxylic acids